Teva Pharmaceuticals (NYSE:TEVA) is often referred to as the biggest generic drugmaker in the world, and its 2.8% dividend yield can look attractive to investors seeking health care exposure in their portfolio. However, the company is facing many headwinds in the coming years. Its top-selling multiple sclerosis drug Copaxone, for instance, is not a generic product and is facing upcoming roadblocks that could stall the company's growth. In the following video, health care analyst Max Macaluso elaborates on the three biggest challenges Teva is facing today.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
The Laundry List of Reasons Behind Teva Pharmaceutical Industries' 48% Tumble in 2017
Teva threw everything but the kitchen sink at its shareholders last year, but the future is beginning to look brighter.
The Big Reason Teva Pharmaceutical Industries Catapulted 28% Higher in December
Plans to "trim the fat" have Wall Street and investors excited.
Billionaire George Soros Is Betting Big Against These 2 Pharma Stocks
Can Valeant and Teva rebound? George Soros' namesake fund doesn't seem to think so.